Physician profile
Marc A Milano
NPI 1477540219
$391,590.52
in general payments reported to CMS, 2019-2025
20 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $22K · 2021: $61K · 2022: $59K · 2023: $119K · 2024: $92K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $170K · Travel and Lodging: $31K · Consulting Fee: $9,530 · Food and Beverage: $7,097 · Honoraria: $4,994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $169,715.00 |
| Travel and Lodging | $31,450.26 |
| Consulting Fee | $9,530.00 |
| Food and Beverage | $7,096.76 |
| Honoraria | $4,994.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $141,776.28 | 2019-2024 | Andexxa, Lokelma |
| Gilead Sciences, INC. | $106,057.58 | 2021-2025 | Veklury |
| Chiesi USA, INC. | $51,106.58 | 2020-2025 | Cleviprex, Curosurf |
| Abbvie INC. | $47,197.53 | 2021-2025 | |
| Bioxcel Therapeutics, INC. | $31,093.25 | 2023-2024 | Igalmi |
| Portola Pharmaceuticals, LLC | $9,950.86 | 2019-2020 | |
| Acelrx Pharmaceuticals, INC. | $2,284.82 | 2019 | |
| Allergan, INC. | $372.90 | 2019 | |
| Csl Behring | $261.06 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $246.41 | 2019-2023 | Xarelto |
| Esperion Therapeutics, INC. | $223.64 | 2020 | |
| Alexion Pharmaceuticals, INC. | $214.84 | 2021-2022 | |
| La Jolla Pharmaceutical Company | $201.19 | 2021 | |
| Acacia Pharma INC | $118.61 | 2021 | |
| Abbott Laboratories | $112.47 | 2024 | I-Stat |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $108.74 | 2024 | Yupelri |
| Covidien Lp | $106.52 | 2019 | |
| Boston Scientific Corporation | $91.06 | 2020 | |
| Agiliti Health, INC. | $51.77 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Milano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.